معرفی
Professor Mohammed Eslam, an esteemed academic at the University of Sydney within the Faculty of Medicine and Health, is a global authority on metabolic dysfunction, liver disease, and liver cancer. His research has redefined fatty liver disease through international consensus, leading to the MAFLD (Metabolic Dysfunction-Associated Fatty Liver Disease) framework, which has been validated in over 10 million patients worldwide. He heads the International Liver Disease Genetics Consortium (7,000 samples across 13 countries) and serves as Deputy Director of the Storr Liver Centre.
- Research Focus: Genetics/epigenetics of liver diseases, fibrosis, personalized medicine, and translational studies
- Editorial Roles: Associate Editor for Sci Rep, Clin Exp Med, and Metab Target Organ Damage (2024-ongoing)
- Prominent Awards: Springer Nature Distinction Awards (2025), WISE Award (2015-2025), Turkish Society of Gastroenterology Symbolic Award (2024)
His 15 most recent articles (2025-2024) span MAFLD epidemiology, genetic risk factors, fibrosis biomarkers (e.g., PRO-C3), and interdisciplinary approaches to chronic liver disease. Collaborations with global societies like APASL and AMAGE have influenced health policy. He mentors PhD students and examines theses internationally, focusing on lean MAFLD pathogenesis and splicing therapies.
Scientific Honors:
- 2015-2025: Westmead Institute WISE Award (10 consecutive years)
- 2025: Springer Nature Editorial Contribution & Author Service Distinction
- 2024: Turkish Society of Gastroenterology Symbolic Award
